PE20210317A1 - Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en celulas vero y composicion de vacuna que la comprende - Google Patents
Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en celulas vero y composicion de vacuna que la comprendeInfo
- Publication number
- PE20210317A1 PE20210317A1 PE2020001491A PE2020001491A PE20210317A1 PE 20210317 A1 PE20210317 A1 PE 20210317A1 PE 2020001491 A PE2020001491 A PE 2020001491A PE 2020001491 A PE2020001491 A PE 2020001491A PE 20210317 A1 PE20210317 A1 PE 20210317A1
- Authority
- PE
- Peru
- Prior art keywords
- yellow fever
- fever virus
- live attenuated
- vero cells
- virus strain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/08—Inactivation or attenuation by serial passage of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invencion se refiere a una cepa del virus de la fiebre amarilla viva atenuada adaptada para crecer en celulas Vero a partir de una subcepa del virus de la fiebre amarilla 17D parental que no esta adaptada para crecer en celulas Vero, donde dicha cepa del virus de la fiebre amarilla viva atenuada es menos neurovirulenta que dicha subcepa del virus de la fiebre amarilla 17D parental
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305405.5A EP3549603A1 (en) | 2018-04-06 | 2018-04-06 | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
PCT/EP2019/058268 WO2019192997A1 (en) | 2018-04-06 | 2019-04-02 | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210317A1 true PE20210317A1 (es) | 2021-02-16 |
Family
ID=62046805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001491A PE20210317A1 (es) | 2018-04-06 | 2019-04-02 | Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en celulas vero y composicion de vacuna que la comprende |
Country Status (15)
Country | Link |
---|---|
US (2) | US11471521B2 (es) |
EP (2) | EP3549603A1 (es) |
JP (1) | JP7370338B2 (es) |
KR (1) | KR20200140292A (es) |
CN (1) | CN111918669A (es) |
AR (1) | AR114471A1 (es) |
AU (1) | AU2019249329A1 (es) |
BR (1) | BR112020018879A2 (es) |
CA (1) | CA3095438A1 (es) |
CO (1) | CO2020011984A2 (es) |
PE (1) | PE20210317A1 (es) |
SG (1) | SG11202009439YA (es) |
TW (1) | TWI835787B (es) |
WO (1) | WO2019192997A1 (es) |
ZA (1) | ZA202006280B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3549603A1 (en) | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009109550A1 (en) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
CA2768997C (en) * | 2009-07-31 | 2017-09-12 | Xcellerex, Inc. | High yield yellow fever virus strain with increased propagation in cells |
AR079970A1 (es) * | 2010-07-23 | 2012-02-29 | Xcellerex Inc | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas |
EP2877208B1 (en) | 2012-07-24 | 2021-05-12 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
EP3549603A1 (en) * | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
-
2018
- 2018-04-06 EP EP18305405.5A patent/EP3549603A1/en not_active Withdrawn
-
2019
- 2019-04-02 US US17/045,322 patent/US11471521B2/en active Active
- 2019-04-02 SG SG11202009439YA patent/SG11202009439YA/en unknown
- 2019-04-02 WO PCT/EP2019/058268 patent/WO2019192997A1/en unknown
- 2019-04-02 PE PE2020001491A patent/PE20210317A1/es unknown
- 2019-04-02 KR KR1020207030059A patent/KR20200140292A/ko not_active Application Discontinuation
- 2019-04-02 TW TW108111634A patent/TWI835787B/zh active
- 2019-04-02 AU AU2019249329A patent/AU2019249329A1/en active Pending
- 2019-04-02 CN CN201980023339.4A patent/CN111918669A/zh active Pending
- 2019-04-02 BR BR112020018879-4A patent/BR112020018879A2/pt unknown
- 2019-04-02 EP EP19714666.5A patent/EP3773701A1/en active Pending
- 2019-04-02 CA CA3095438A patent/CA3095438A1/en active Pending
- 2019-04-02 JP JP2020554449A patent/JP7370338B2/ja active Active
- 2019-04-05 AR ARP190100906A patent/AR114471A1/es unknown
-
2020
- 2020-09-28 CO CONC2020/0011984A patent/CO2020011984A2/es unknown
- 2020-10-09 ZA ZA2020/06280A patent/ZA202006280B/en unknown
-
2021
- 2021-11-05 US US17/453,758 patent/US11452772B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11452772B2 (en) | 2022-09-27 |
SG11202009439YA (en) | 2020-10-29 |
CA3095438A1 (en) | 2019-10-10 |
CO2020011984A2 (es) | 2021-02-08 |
ZA202006280B (en) | 2022-06-29 |
US20220047692A1 (en) | 2022-02-17 |
RU2020136260A (ru) | 2022-05-06 |
EP3773701A1 (en) | 2021-02-17 |
EP3549603A1 (en) | 2019-10-09 |
TWI835787B (zh) | 2024-03-21 |
WO2019192997A1 (en) | 2019-10-10 |
KR20200140292A (ko) | 2020-12-15 |
TW202003028A (zh) | 2020-01-16 |
JP2021520384A (ja) | 2021-08-19 |
AR114471A1 (es) | 2020-09-09 |
JP7370338B2 (ja) | 2023-10-27 |
US11471521B2 (en) | 2022-10-18 |
CN111918669A (zh) | 2020-11-10 |
US20210154289A1 (en) | 2021-05-27 |
AU2019249329A1 (en) | 2020-12-03 |
BR112020018879A2 (pt) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
CO2017004119A2 (es) | Partículas tipo virus modificadas de cmv | |
MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
UY36395A (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso. | |
MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
CL2019001200A1 (es) | Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta. | |
CU24510B1 (es) | Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes | |
AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
UY32274A (es) | Pestivirus quimericos | |
CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
WO2016100615A3 (en) | Methods and composition for neutralization of influenza | |
CU24682B1 (es) | Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados | |
PE20210317A1 (es) | Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en celulas vero y composicion de vacuna que la comprende | |
MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
NZ744054A (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
PE20190225A1 (es) | Un metodo para reducir la contaminacion de huevo | |
MX2018001251A (es) | Respuesta inmunitaria potenciada de las especies porcinas. | |
EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
MX2018003173A (es) | Vacunas de salmonella choleraesuis-salmonella typhimurium. | |
AR117942A1 (es) | Vacunas contra el zika, composiciones inmunogénicas y métodos que las utilizan | |
AR095118A1 (es) | Un procedimiento de inactivación viral en composición que comprende factor vii | |
IL259451B (en) | A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens |